Abbott receives warning letter for FreeStyle Libre sensors from the FDA following an inspection. The letter focuses on problems with Abbott's tests and verification of accuracy of their CGMs.
Details of Insulet's long-term vision and new details about Omnipod 6, alongside upgrades to existing systems and a fully closed-loop option for people with type 2 diabetes.
A recent update to the Libre 3 app in the US now enables users to snap their meal to learn how their glucose will change. At the same time the app has made it possible to see levels on a smartwatch.
What longer-wear monitoring, fewer sensor changes and tighter integration could mean for future CGM and pump choices.
A look at the company's dramatic share price drop, iLet patient Numbers, CGM partnership with Abbott & the outlook for rollout in the UK/EU.
A quick overview of other recent news relating to diabetes management and/or CGMs. Just in case you missed these!
We reflect on Dexcom's performance in 2025 and get up-to-date with news of their plans for a G8 sensor and international expansion.
FDA Commissioner Martin Makary recently highlighted the role of CGMs in preventing chronic conditions, questioning why they are only available on prescription. Could there be any benefit to the diabetes community of a policy change?
New medtech startup, Luna Health, based in the US, have raised $23.6 million to advance a patch pump designed specifically for overnight use only.
News that Abbott have agreed to collaborate with 4 pump providers for hybrid closed loop with their future combined glucose - ketone sensor.
News that Eversense 365 has been named Best New Technology Solution for Diabetes Management in the 2025.
FDA approval of Simplera Sync sensor paired with MiniMed™ 780G insulin pump.
